CRVS logo

CRVS Corvus Pharmaceuticals, Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$9.67
-0.34 (-3.40%)

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another pro…

Market Cap: $815.69Mwww.corvuspharma.com

Price

No data yet.

Social Signal Score

49
5d
—
30d
48
6 mentions
—
60d
49
7 mentions
—
90d
49
8 mentions
—
news: 8

Analyst Ratings

13 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 1Sell 0Strong Sell 0
Avg price target$27+179.2%
Low $27Median $27High $27
Current Consensus

Revenue

$0.00
$0.00
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.24
$-0.26–$-0.20
3 analysts
FY2026
$-0.81
$-0.86–$-0.79
5 analysts
FY2027
$-1.05
$-1.20–$-0.95
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Richard A. Miller
Sector
Healthcare
Industry
Biotechnology
Employees
37
Beta
0.86
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
28.66
www.corvuspharma.com